Categories

Cables & Cable Assemblies

Consumer Products

Electronic Components & Electrochemical Materials

Fabrics

Fibers

Filtration

Medical Products

Ozonation Modules

Pharmaceutical & Biopharmaceutical

Sealants

Venting

News

Shared Purpose: Gore’s 2022 Enterprise New Sustainability Update

Posted July 11, 2023

In this 2022 Enterprise Sustainability Update our sustainability efforts — across purposeful innovation, environmental stewardship, and enhancing our social impact — stay true to our core values and uphold our brand promise: Together, improving life.

Press Release

GORE PHARMBIO INTRODUCES 250ML, 500ML AND 1L PROTEIN CAPTURE DEVICES WITH PROTEIN A TO DELIVER CONSISTENT SCALABILITY AND INCREASED PRODUCTIVITY ACROSS SIZES

Posted April 11, 2023

W. L. Gore & Associates, Inc. (“Gore”), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its 250mL, 500mL and 1L GORE® Protein Capture Devices with Protein A. The offerings follow commer-cial availability of its 116mL and 232mL sizes introduced in mid 2022.

Press Release

AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies

Posted December 12, 2022

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the global CDMO’s contract development and manufacturing services. By using GORE and AGC Biologics, biopharmaceutical companies can improve downstream purification processes, eliminate column bioburden issues, increase product material yields in the research and development (R&D) stages, and help lower costs for clinical manufacturing.

Press Release

Gore Acquires InnAVasc Medical, Inc.

Posted August 12, 2022

W. L. Gore & Associates, Inc. (Gore) announced the acquisition of InnAVasc Medical, Inc., a privately held medical technology company focused on advancing care for patients with end stage renal disease who utilize graft circuits for dialysis treatment.

Press Release

Gore PharmBIO Introduces 116mL and 232mL Protein Capture Devices with Protein A to Increase Productivity and Throughput for Antibody Purification

Posted April 5, 2022

W.L. Gore & Associates, Inc. continues to build on its growing portfolio of protein capture devices with the introduction of its new 116mL and 232mL GORE® Protein Capture Devices with Protein A. The offerings strengthen Gore’s chromatography device portfolio and follow the commercial availability of its 58mL Protein Capture Device in Q4 of 2021.

Press Release

Physicians in the U.S. Begin Commercial Use of the GORE® Excluder® Conformable AAA Endoprosthesis With Active Control System

Posted March 29, 2021

Today, W. L. Gore & Associates, Inc. (Gore) announces the first use of the FDA approved GORE® EXCLUDER® Conformable AAA Endoprothesis with ACTIVE CONTROL System in cases outside of clinical trials. Cases were successfully performed by Robert Rhee, M.D. with Mahmoud Almadani, M.D., in Brooklyn, New York and by Gustavo Oderich, M.D. with Naveed Saqib, M.D., in Houston, Texas.

Press Release

W. L. Gore & Associates Announces Encouraging Six-month Results with Its Novel Biosynthetic Tissue Valve

Posted November 18, 2020

W. L. Gore & Associates, Inc. (Gore), a global leader in providing solutions for cardiovascular disease, today announced encouraging clinical results from its early feasibility study evaluating the safety and performance of its pulmonary valved conduit, an investigational device.

Press Release

Gore introduces new 9.0mL Protein Capture Device for affinity chromatography

Posted March 20, 2020

Gore is adding to it's range of affinity chromatography devices with the larger 9.0 mL size device for applications in process development, pre-clinical and early clinical drug development. This launch is significant because it demonstrates that this innovative membrane technology can be scaled to larger sizes without losing performance benefits.

Press Release

Gore Receives CE Mark for the GORE® CARDIOFORM ASD Occluder for the Treatment of Atrial Septal Defects in Europe

Posted October 2, 2019

W. L. Gore & Associates has introduced the newest member of its family of occluders, the GORE® CARDIOFORM ASD Occluder, which has received CE Mark. The device offers physicians a clinically proven design in a device that, in a recent study, met its primary endpoint for the percutaneous, transcatheter closure of ostium secundum atrial defects (ASDs).

Press Release

GORE® ENFORM Biomaterial Earns Innovative Technology Designation from Vizient, Inc.

Posted July 17, 2019

W. L. Gore & Associates announced that GORE® ENFORM Biomaterial for use in abdominal wall reconstruction procedures recently received the Innovative Technology designation from Vizient, Inc., the largest member-driven health care performance improvement company in the U.S.

Press Release

First U.S. Patient Receives GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL

Posted July 10, 2019

Gore announces the first U.S. implant of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. This first case follows the recent FDA approval for this new device.

Press Release

GORE® CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects

Posted June 4, 2019

W. L. Gore & Associates announced the U.S. Food and Drug Administration’s (FDA’s) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ostium secundum atrial septal defects (ASDs).

Press Release

Gore Receives FDA Approval for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL

Posted May 15, 2019

W. L. Gore & Associates, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for commercial distribution for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System, a unique Thoracic Endovascular Aortic Repair (TEVAR) solution combining new levels of control with the proven legacy and trusted performance of the Conformable GORE® TAG® Device.

Load more news